-+ 0.00%
-+ 0.00%
-+ 0.00%

Evercore ISI Group Maintains Outperform on Revolution Medicines, Raises Price Target to $340

Benzinga·11/05/2026 14:31:40
语音播报
Evercore ISI Group analyst Cory Kasimov maintains Revolution Medicines (NASDAQ:RVMD) with a Outperform and raises the price target from $320 to $340.